MET and pancreatic neoplasm: Then, we explored the signaling pathways of aberrant RON and MET expression in pancreatic cancer, and evaluated the significance of RON and MET as therapeutic targets of TKIs targeting RON and/or MET in pancreatic cancer, further providing new means and therapy for treating pancreatic cancer in the future.